Supernus Pharmaceuticals, Inc. $SUPN Shares Bought by Sofinnova Investments Inc.

Sofinnova Investments Inc. raised its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 46.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 553,095 shares of the specialty pharmaceutical company’s stock after acquiring an additional 176,029 shares during the quarter. Sofinnova Investments Inc.’s holdings in Supernus Pharmaceuticals were worth $27,489,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of SUPN. Torren Management LLC acquired a new stake in Supernus Pharmaceuticals during the 4th quarter worth about $49,000. EverSource Wealth Advisors LLC acquired a new stake in Supernus Pharmaceuticals during the 2nd quarter worth about $51,000. Smartleaf Asset Management LLC raised its holdings in Supernus Pharmaceuticals by 30.8% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 268 shares during the period. Hantz Financial Services Inc. raised its holdings in Supernus Pharmaceuticals by 73.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 458 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Supernus Pharmaceuticals during the 2nd quarter worth about $55,000.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SUPN. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Finally, Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 23rd. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $62.17.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 7,250 shares of the company’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $49.60, for a total value of $359,600.00. Following the transaction, the vice president owned 17,044 shares in the company, valued at $845,382.40. This represents a 29.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.50% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Price Performance

Shares of SUPN opened at $43.86 on Tuesday. The company has a market capitalization of $2.55 billion, a price-to-earnings ratio of -86.00, a P/E/G ratio of 0.95 and a beta of 0.55. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $30.83 and a fifty-two week high of $59.68. The business’s 50-day moving average is $48.55 and its 200-day moving average is $49.55.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.